Physician profile
Gurpreet Lamba
NPI 1427294271
$66,765.16
in general payments reported to CMS, 2019-2025
88 companies · $7,435 in 2025
The $7,435 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,958 · 2020: $9,464 · 2021: $5,343 · 2022: $6,510 · 2023: $20K · 2024: $11K · 2025: $7,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $9,193 · Honoraria: $8,308 · Travel and Lodging: $4,434 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,342.50 |
| Food and Beverage | $9,193.25 |
| Honoraria | $8,308.00 |
| Travel and Lodging | $4,434.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $212.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $11,598.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $8,739.47 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Avyxa Pharma, LLC | $4,031.19 | 2025 | |
| Beigene USA, INC. | $3,065.84 | 2022-2025 | Brukinsa, Tevimbra |
| Eisai INC. | $2,743.15 | 2019-2025 | |
| Abbvie INC. | $2,652.29 | 2019-2025 | |
| Taiho Oncology, INC. | $2,633.89 | 2019-2025 | |
| Astellas Pharma US INC | $2,629.58 | 2019-2024 | Padcev, Xtandi, Xospata |
| Daiichi Sankyo INC. | $2,559.52 | 2020-2025 | Vanflyta, Enhertu, Injectafer |
| Dova Pharmaceuticals | $2,382.74 | 2019-2020 | |
| Celgene Corporation | $2,246.36 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Blueprint Medicines Corporation | $2,204.06 | 2020-2024 | Ayvakit |
| G1 Therapeutics, INC. | $1,534.13 | 2021-2023 | Cosela |
| Epizyme, INC. | $1,308.21 | 2021-2022 | |
| Pfizer INC. | $1,175.74 | 2019-2025 |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,163.96 | 2019-2025 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $1,059.70 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Secura Bio, INC. | $1,016.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $900.49 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Adaptive Biotechnologies Corporation | $842.69 | 2020-2025 | Clonoseq |
| Janssen Biotech, INC. | $745.11 | 2019-2025 | Tecvayli, Carvykti, Rybrevant |
| Seagen INC. | $615.79 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Incyte Corporation | $567.61 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $531.33 | 2020-2023 | Xgeva, Nplate |
| Bayer Healthcare Pharmaceuticals INC. | $485.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $485.11 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $409.12 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $371.42 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Genzyme Corporation | $363.99 | 2019-2025 | |
| Lilly USA, LLC | $288.41 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Stemline Therapeutics INC. | $284.91 | 2022-2025 | Orserdu |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Foundation Medicine, INC. | $264.77 | 2020-2023 | Foundationone Liquid Cdx |
| Kite Pharma, INC. | $254.52 | 2020-2025 | Yescarta |
| Novocure Gmbh | $250.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.72 | 2019-2024 | Ninlaro, Exkivity, Vpriv |
| Karyopharm Therapeutics INC. | $233.78 | 2020-2025 | Xpovio |
| Puma Biotechnology, INC. | $231.72 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $216.64 | 2021-2025 | Monoferric |
| Array Biopharma INC | $214.95 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Coherus Oncology, INC. | $200.41 | 2020-2025 | Loqtorzi |
| Exelixis INC. | $190.81 | 2021-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $186.38 | 2023-2025 | |
| Mirati Therapeutics, INC. | $166.97 | 2023-2024 | Krazati |
| Morphosys, US INC. | $130.07 | 2021-2023 | Monjuvi |
| Sirtex Medical INC | $123.76 | 2019-2022 | |
| Silk Road Medical, INC. | $122.04 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Dendreon Pharmaceuticals LLC | $114.73 | 2020-2025 | Provenge |
| Pharmacyclics LLC, An Abbvie Company | $114.73 | 2019-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $96.09 | 2022-2025 | Fotivda |
| Tempus Ai, INC | $94.57 | 2024-2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $85.87 | 2019-2024 | Tavalisse, Rezlidhia |
| Regeneron Healthcare Solutions, INC. | $75.79 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $72.41 | 2021-2025 | Qinlock, Romvimza |
| Myovant Sciences INC. | $72.40 | 2021-2022 | |
| Sobi, INC | $71.49 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $70.64 | 2021-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $69.25 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $68.70 | 2019-2025 | |
| Apellis Pharmaceuticals, INC. | $67.96 | 2022-2023 | Empaveli |
| Sun Pharmaceutical Industries INC. | $63.45 | 2021-2024 | Yonsa, Odomzo |
| Emd Serono, INC. | $58.38 | 2020-2023 | Tepmetko, Bavencio |
| Acrotech Biopharma INC. | $56.18 | 2021-2023 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $52.13 | 2024-2025 | Onivyde, Somatuline Depot |
| Springworks Therapeutics, INC. | $42.20 | 2024-2025 | Ogsiveo |
| Mylan Institutional INC. | $41.63 | 2019-2022 | |
| Verastem, INC. | $38.82 | 2019 | |
| Aadi Bioscience, INC. | $35.09 | 2023-2024 | Fyarro |
| Geron Corporation | $32.98 | 2024-2025 | Rytelo |
| Acceleron Pharma, INC. | $26.65 | 2021 | |
| Menarini Silicon Biosystems, INC. | $26.12 | 2024 | |
| Spectrum Pharmaceuticals INC. | $23.11 | 2023 | Rolvedon |
| Beone Medicines USA, INC. | $21.34 | 2025 | Brukinsa |
| Genmab U.S., INC. | $20.41 | 2025 | Tivdak |
| Alnylam Pharmaceuticals INC. | $18.15 | 2025 | Givlaari |
| Sumitomo Pharma America, INC. | $17.81 | 2025 | Orgovyx |
| Invivyd INC | $17.65 | 2025 | Pemgarda |
| Fresenius Kabi USA, LLC | $17.56 | 2023 | Stimufend |
| Janssen Pharmaceuticals, INC | $17.23 | 2022 | |
| Cti Biopharma Corp. | $14.99 | 2023 | Vonjo |
| Tolmar Pharmaceuticals, INC. | $14.66 | 2019 | |
| Kyowa Kirin, INC. | $14.65 | 2022 | |
| Immunogen, INC. | $14.49 | 2024 | Elahere |
| Pharmaessentia USA Corporation | $14.27 | 2022 | |
| Aimmune Therapeutics, INC. | $13.76 | 2024 | |
| Heron Therapeutics, INC. | $13.61 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $13.52 | 2020 | |
| Tg Therapeutics, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Lamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.